LYMPHIR Institutional Orders Surge 78% Quarter-Over-Quarter
Citius Oncology reported significant commercial momentum for its cancer drug LYMPHIR, with new institutional orders rising 78% due to expanding formulary approval. This growth reflects in increased wholesale demand, positioning the company to accelerate top-line revenue through the remainder of the year.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day